drugset
drugset / Trial / NCT00103519

Study of DITPA in Patients With Congestive Heart Failure

NCT00103519 ↗

Phase 2 Terminated 86 enrolled Titan Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3. DITPA is an investigational agent.

Timeline

Start
2004-12
Primary completion
2006-12
Completion
2006-12

Outcome

Outcome not reported

Stopped: “Study terminated for reasons unrelated to safety or efficacy.”

Drugs

EvaluationDrugModalityDoseRoute
Subject 3,5-diiodothyropropionic acid Small molecule 90 mg Oral
Subject 3,5-diiodothyropropionic acid Small molecule 180 mg Oral

Indications

congestive heart failure